Interventions aimed at ameliorating early organ injury thereby improving early organ function face unique challenges in translation, including clinical trial design and the extreme challenge of conducting trials in DBD (and DCD) donors as injury begins in the deceased donor. However, the administration of novel agents to deceased donors is fraught with ethical, logistical, and regulatory barriers that obstruct innovation. There is a broad-based effort involving HRSA, AST, ASTS, AOPO, and other major multi-disciplinary stakeholders to identify, discuss, and potentially resolve the key barriers.
Univ of California, San Francisco
You must be logged in and own this session in order to